LEADER 01178nam 2200385 450 001 9910671629103321 005 211118083030.5 035 $a(CKB)5450000000176029 035 $a(MiAaPQ)EBC6777589 035 $a(EXLCZ)995450000000176029 100 $a20210921d2020 uy 0 101 0 $aspa 135 $aurcnu|||||||| 181 $ctxt$2rdacontent/spa 182 $cc$2rdamedia/spa 183 $acr$2rdacarrier/spa 200 10$aCostos y Presupuestos para financieros junior /$fFe?lix Armando Va?squez Rojas 210 1$aBogota, Colombia :$cGrupo Editorial Nueva Legislacio?n SAS,$d2020. 215 $a1 recurso en li?nea (138 pa?ginas) 300 $aI?ndice. 311 $a958-52652-5-7 320 $aBibliografi?a. 606 $aFinance$xBudget 606 $aFinanzas$xPresupuesto 608 $aLibros electronicos. 615 4$aFinance$xBudget. 615 4$aFinanzas$xPresupuesto. 676 $a332 700 $aVa?squez Rojas$b Fe?lix Armando$01334581 801 0$bFINmELB 801 1$bFINmELB 906 $aBOOK 912 $a9910671629103321 996 $aCostos y Presupuestos para financieros junior$93046283 997 $aUNINA LEADER 03969nam 2201285z- 450 001 9910576879403321 005 20220621 035 $a(CKB)5720000000008381 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/84510 035 $a(oapen)doab84510 035 $a(EXLCZ)995720000000008381 100 $a20202206d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aAge-Related Macular Degeneration and Diabetic Retinopathy 210 $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 online resource (228 p.) 311 08$a3-0365-4210-8 311 08$a3-0365-4209-4 330 $aThis reprint includes contributions from leaders in the field of personalized medicine in ophthalmology. The contributions are diverse and cover pre-clinical and clinical topics. We hope you enjoy reading the articles. 606 $aBiology, life sciences$2bicssc 606 $aResearch and information: general$2bicssc 610 $a3D models 610 $a577-nm laser 610 $aage-related macular degeneration 610 $aAMD 610 $aanti-vascular endothelial growth factor 610 $aanti-VEGF 610 $aanti-VEGF therapy 610 $aAT1-receptor 610 $aautoantibodies 610 $aautofluorescence 610 $abiomarker 610 $abiomarkers 610 $ablood-neural barriers 610 $aC4 610 $acentral area thickness 610 $achoroidal neovascularization 610 $aclassification 610 $acomplement system 610 $adiabetic macular edema 610 $adiabetic macular oedema 610 $adiabetic retinopathy 610 $adiabetic retinopathy severity scale 610 $adisease modeling 610 $aedema 610 $aETDRS classification 610 $aethnicity 610 $afactor I 610 $ageneral practice 610 $agenetic variants 610 $aglucose variability 610 $aglycemic gap 610 $aHDL 610 $aindicators 610 $ainner blood-retinal barrier 610 $aintravitreal aflibercept 610 $alaser fixed parameters 610 $aleakage index 610 $amachine learning 610 $amass spectrometry 610 $ametabolites 610 $amicroaneurysms 610 $amicrophysiological systems 610 $amicroRNA 610 $an/a 610 $aneovascular age-related macular degeneration 610 $aneovascularization 610 $aneurovascular unit 610 $aOCT 610 $aoptical coherence tomography 610 $aorgan-on-a-chip 610 $apanretinal leakage index 610 $aPAR1 610 $apersonalized medicine 610 $aphenotypes 610 $aprecision medicine 610 $aprogression 610 $aquantitative biomarkers 610 $areal-life 610 $aretina 610 $aretinal imaging 610 $aretinal thickness 610 $aretinopathy 610 $arisk factors 610 $asemi-quantitative multiplex profilin 610 $asubthreshold micropulse laser 610 $atomography 610 $atype 2 diabetes 610 $aultra-widefield fluorescein angiography 610 $avariability 610 $aVEGF-A 610 $aVEGF-B 610 $aVEGF-receptor 2 610 $avisual acuity 610 $avisual prognosis 610 $avitronectin 615 7$aBiology, life sciences 615 7$aResearch and information: general 700 $aWestenskow$b Peter D$4edt$01293852 702 $aEbneter$b Andreas$4edt 702 $aWestenskow$b Peter D$4oth 702 $aEbneter$b Andreas$4oth 906 $aBOOK 912 $a9910576879403321 996 $aAge-Related Macular Degeneration and Diabetic Retinopathy$93022783 997 $aUNINA